

WHAT IS CLAIMED IS

1. Stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer).
2. A pharmaceutical composition comprising stable amorphous 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer).
3. A method of treating bacterial infections in a mammal using a pharmaceutical composition of claim 2.
4. A pharmaceutical composition comprising compound of claim 1 wherein the stable amorphous cefdinir is combined with a polymer.
5. A pharmaceutical composition comprising compound of claim 1 wherein the stable amorphous cefdinir is combined with a amorphous anionic polymer with an acid dissociation constant greater than 2.
6. A pharmaceutical composition of claim 4 comprising the polymer Eudragit.
7. A pharmaceutical composition comprising compound of claim 1 wherein the stable amorphous cefdinir is combined with an amorphous polymer.
8. A pharmaceutical composition of claim 7 comprising a polymer selected from the group consisting of polyvinylpyrrolidone and HPMCs.
9. A process for producing stable amorphous cefdinir comprising combining cefdinir monohydrate in a methanolic solution and evaporating the solution.
10. A process for producing stable amorphous cefdinir comprising combining cefdinir monohydrate in an organic solvent in which the solubility of cefdinir monohydrate is greater than 0.5 mg/ml and evaporating the solution.